Company Overview
Snapshot
Founded in April 2019 by Irad Kuhnreich and Eviatar Kuhnreich, Xmetix operates with 1–10 employees. The company has secured funding across two rounds, with its October 2024 funding round from NGT HealthCare II.
Business overview
Xmetix is advancing battlefield and emergency medicine through its proprietary technology, including the TAK710, an automated tourniquet designed to eliminate human error in critical bleeding control. This device offers one-button activation, precise pressure management, and extended stabilization, aiming to reduce blood loss and enhance survival rates. Xmetix serves military, first responders, and civilian markets, operating within the Aerospace, Defense & HLS, and Health Tech & Life Sciences sectors.
Strategic signal
Xmetix's October 2024 funding round, led by NGT HealthCare II, signals continued investor confidence in its automated tourniquet technology. This investment underscores the perceived market need for advanced, reliable hemorrhage control solutions in tactical and emergency medicine, suggesting a potential for broader adoption and market expansion for the company's patented products.
Log in to access full profile ›Company Intelligence Q&A
- What is Xmetix's core product?
- Xmetix's core product is the TAK710, the world’s first fully automated tourniquet, designed to provide precise and rapid hemorrhage control for military, first responders, and civilian use.
- When was Xmetix founded and by whom?
- Xmetix was founded in April 2019 by co-founders Irad Kuhnreich and Eviatar Kuhnreich.
- What markets does Xmetix target with its products?
- Xmetix targets military, first responders, and civilian markets with its automated tourniquet technology, which is already in use by elite military units.
- What is the primary sector Xmetix operates in?
- Xmetix's primary sector is Aerospace, Defense & HLS, with additional operations in Digital Health and Medical Technologies.